Ozempic for weight loss, the realistic picture.

The honest framing

A point of confusion worth settling early: Ozempic and Wegovy are the same molecule (semaglutide) made by the same company, but marketed and dosed differently. Ozempic is approved by India's CDSCO for type 2 diabetes at maximum 1 mg weekly. Wegovy is approved specifically for chronic weight management at a maintenance dose of 2.4 mg weekly.

Almost all of the high-quality weight-loss evidence — the STEP trials — was generated with the 2.4 mg dose, i.e., the Wegovy regimen. When patients use Ozempic for weight loss in India, they are using it off-label, often at sub-maximal weight-management doses. A responsible Indian clinical practice will clarify which product, which dose, and which indication is being prescribed before any pen is dispensed. For the molecule in detail, see our semaglutide guide.

Who should actually be considered for treatment in India?

This is the most under-discussed question in Indian GLP-1 conversations. International eligibility frameworks were built around Caucasian BMI distributions. They under-diagnose Indian metabolic disease.

BMI thresholds — international vs South Asian

The WHO international BMI categories (overweight ≥25, obesity ≥30 kg/m²) systematically miss the "thin-fat" Asian Indian phenotype — relatively low subcutaneous mass but high visceral adiposity, insulin resistance and dyslipidaemia at a BMI that would be called "normal" in a European population.

In 2009, an Indian consensus group reviewed by the Indian Council of Medical Research established lower cut-offs:

• Normal: BMI 18.5–22.9 kg/m²
• Overweight: BMI 23.0–24.9 kg/m²
• Obesity: BMI ≥25.0 kg/m²
• Abdominal obesity: waist circumference ≥90 cm in men, ≥80 cm in women

The ICMR-INDIAB-23 study (2024) confirmed that metabolic obesity — two or more cardiometabolic risk factors with a high waist circumference — is highly prevalent in Indians at BMI levels far below 30.

The working clinical framework

• BMI ≥30 — eligible without an additional comorbidity.
• BMI ≥27 with one weight-related comorbidity (T2D, prediabetes, hypertension, dyslipidaemia, OSA, NAFLD, PCOS) — STEP-1 inclusion criterion, standard regulatory threshold globally.
• BMI ≥25 (Asian-Indian obesity) with multiple metabolic markers — elevated HbA1c, raised triglycerides, low HDL, elevated ALT, high waist-to-height ratio, or a confirmed PCOS or MASLD diagnosis — can be considered under Indian-adapted clinical judgement.
• BMI 23–24.9 in isolation — not an indication. Lifestyle therapy is first-line.

PCOS as an eligibility lever

In an Indian woman with PCOS, candidacy is driven less by absolute BMI and more by the metabolic phenotype: insulin resistance on HOMA-IR, impaired fasting glucose, raised triglycerides, anovulatory cycles unresponsive to lifestyle and metformin. Published evidence shows roughly 80% of obese PCOS patients achieve ≥5% weight loss on low-dose semaglutide, with 80% of responders restoring menstrual regularity by six months. See our complete PCOS guide.

Contraindications

Semaglutide is contraindicated in: personal or family history of medullary thyroid carcinoma (MTC); Multiple Endocrine Neoplasia syndrome type 2 (MEN-2); known hypersensitivity; pregnancy or active plans to conceive (must be stopped at least two months before planned pregnancy); type 1 diabetes; breastfeeding.

Strong cautions: history of pancreatitis; severe gastroparesis; active symptomatic gallbladder disease; severe renal impairment; proliferative diabetic retinopathy; planned general anaesthesia or deep sedation (aspiration risk); concurrent insulin or sulphonylureas (hypoglycaemia risk). For thyroid-specific nuance, see our thyroid and weight guide.

What the evidence actually shows

STEP-1 (2021) — the headline efficacy trial

STEP-1 randomised 1,961 adults without type 2 diabetes (BMI ≥30, or ≥27 with a weight-related comorbidity) to semaglutide 2.4 mg or placebo, both with lifestyle intervention, over 68 weeks.

Mean body-weight change: −14.9% with semaglutide vs −2.4% with placebo.

Responder distribution (semaglutide vs placebo):

• ≥5% loss: 86.4% vs 31.5%
• ≥10% loss: 69.1% vs 12.0%
• ≥15% loss: 50.5% vs 4.9%
• ≥20% loss: 32.0% vs 1.7%
• <5% loss (non-responders): approximately 13.6% of the semaglutide arm

The crucial Indian-relevant interpretation: roughly one in seven semaglutide patients does not respond meaningfully, and a further proportion responds modestly. The "everyone loses 15%" headline is a mean, not a guarantee. Conversely, about a third of patients lose ≥20%, which approaches the lower zone of bariatric-surgery outcomes.

STEP-5 (2022) — does it last at two years?

STEP-5 randomised 304 adults (mean baseline BMI 38.5) to semaglutide 2.4 mg or placebo for 104 weeks. Mean weight change at week 104: −15.2% vs −2.6%. Weight loss reached a plateau around week 60 and was maintained, not extended, through week 104. Improvements in HbA1c, systolic blood pressure and lipids were sustained at two years.

STEP-4 and STEP-1 extension — what happens after stopping

STEP-4 ran a 20-week semaglutide lead-in (mean loss ~10.6%), then randomised participants to continue semaglutide or switch to placebo for a further 48 weeks. The placebo-switch arm regained weight; the continuation arm lost another ~7.9 percentage points.

The STEP-1 off-treatment extension followed 327 participants for a year after 68 weeks of treatment ended. By week 120 (one year off treatment), participants had regained 11.6 of those 17.3 percentage points — approximately two-thirds of the prior weight loss returned within 12 months of cessation, and most cardiometabolic gains reverted toward baseline.

The clinical implication is unambiguous: obesity is a chronic disease, and semaglutide is an ongoing therapy, not a 12-week protocol.

SELECT (2023) — cardiovascular outcomes

SELECT randomised 17,604 patients aged ≥45 with BMI ≥27 and established atherosclerotic cardiovascular disease — but without diabetes — to semaglutide 2.4 mg or placebo. The primary composite outcome (cardiovascular death, non-fatal MI, non-fatal stroke) was reduced by 20%. Directly relevant to Indian patients with a BMI of 28 and prior MI.

Side-effect profile — what to expect

Across STEP-1 and STEP-5, the side-effect signal is overwhelmingly gastrointestinal and dose-titration-related:

• Any GI adverse event: 74.2% with semaglutide vs 47.9% with placebo in STEP-1; 82.2% vs 53.9% in STEP-5.
• Nausea: ~44%; diarrhoea ~30%; vomiting ~24%; constipation ~24%. Majority mild-to-moderate, concentrated during dose escalation.
• Discontinuation due to GI adverse events: 4.5% with semaglutide vs 0.8% with placebo in STEP-1.

Serious events of interest: rare pancreatitis; gallbladder events (cholelithiasis/cholecystitis) consistent with rapid weight loss in general; boxed-warning thyroid C-cell tumour signal from rodent studies but no confirmed human MTC in trial populations; rare diabetic retinopathy worsening; acute kidney injury from severe vomiting/dehydration; pulmonary aspiration under anaesthesia.

Indian-specific considerations

Vegetarian protein adequacy at appetite-suppressed doses

This is the single most under-addressed clinical issue in Indian GLP-1 practice. Semaglutide reduces appetite by 30–40% at maintenance dose. For an Indian vegetarian eating dal, sabzi, roti and curd, baseline protein intake is often already 0.6–0.8 g/kg/day — below the 1.0–1.2 g/kg/day required to preserve lean mass during caloric deficit.

When appetite drops, this gap widens fast. Loss of lean mass during semaglutide treatment is real and is the leading reversible cause of metabolic slowdown and post-cessation regain.

Practical Indian targets: paneer (200 g delivers ~36 g protein), dal at every meal, soya chunks, tofu, Greek yoghurt, sprouts, eggs (for ovo-vegetarians), and whey or pea-protein supplementation where intake remains short. Pulses alone will not get most patients to target at suppressed appetite. A weight-management programme that does not write a protein prescription is incomplete.

PCOS — what the evidence supports for Indian women

Indian women with PCOS represent perhaps the largest under-served candidate population. The clinical pattern in published trials is consistent:

• Approximately 80% of obese PCOS patients achieve ≥5% weight loss on semaglutide, even at sub-maximal (0.5–1.0 mg) doses.
• Among those who lose weight, ~80% restore menstrual regularity within six months.
• HOMA-IR, fasting glucose and androgen levels improve; hirsutism scores fall over 9–12 months.
• Fertility planning is critical: because semaglutide must be stopped at least two months before conception, women actively trying to conceive should not be on therapy. The framework is "lose weight first, washout, then conceive."

Festival eating and adherence

Indian eating is socially mandatory. Diwali, Eid, Christmas, weddings, anniversaries, family lunches — refusal is read as rudeness. GLP-1 therapy genuinely changes how patients tolerate large meals: nausea after over-eating is common and not pleasant. Adherence problems in Indian patients cluster around skipping doses before known feast days, abandoning therapy after a single bad GI episode, and inability to attend follow-ups during festival weeks.

None of this is in the trial data, but all of it determines real-world results.

A decision framework

Consider GLP-1 therapy if:

• BMI ≥27 with one weight-related comorbidity; or BMI ≥30 without; or, by Asian-Indian standards, BMI ≥25 with multiple metabolic markers.
• You have prediabetes or type 2 diabetes inadequately controlled by metformin alone. See our diabetes guide.
• You have established cardiovascular disease and BMI ≥27 (SELECT-eligible profile).
• You've completed at least three to six months of structured lifestyle intervention without meaningful response.
• You're willing to commit to multi-year therapy and understand the regain trajectory after cessation.

Consider alternatives or delay if:

• BMI <25 with no metabolic disease — lifestyle and behavioural therapy first.
• Active or recent pancreatitis; personal or family MTC/MEN-2.
• Pregnancy planned within the next 2–3 months.
• Severe gastroparesis or uncontrolled gastrointestinal disease.
• BMI ≥40 with significant comorbidities and a strong surgical candidate profile — bariatric surgery may be more cost-effective long-term.
• Untreated proliferative diabetic retinopathy or active eating disorder requiring psychiatric care.

The honest answer to "should I take Ozempic?" is rarely a flat yes or no. It is "here is your specific eligibility profile; here is what the evidence predicts for your population; here is what happens if you stop." That's what your AIIMS-trained Kaivo physician spends the consult sorting out. For the head-to-head with tirzepatide, see our Ozempic vs Mounjaro comparison.

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989–1002.
2. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083–2091.
3. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP-4). JAMA. 2021;325(14):1414–1425.
4. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP-1 extension). Diabetes Obes Metab. 2022;24(8):1553–1564.
5. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232.
6. Misra A, Vikram NK, Gupta R, et al. Waist circumference cutoff points and action levels for Asian Indians for identification of abdominal obesity. Int J Obes. 2006;30(1):106–111.